Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes IndexGuy you may be right. “I may be crazy” - Billy Joel
If there was any good news, that would be mentioned. I bet there is a delay or something. Might not be bad, but there are other 10-baggers out there. WITH institutional ownership.
When there has been good news to report, they have put that in the conference call pr notice. When there was bad news, they merely say there is a conference call scheduled. I have sold half in advance of the call.
Perhaps annual meeting coming up, perhaps Prostagene, perhaps REAL funding ....
CytoDyn to Hold Investment Community Conference Call on September 13, 2018 $CYDY Https://seekingalpha.com/pr/17265822
Institutional holders : 0.1%
I would. No confidence in Mgmt.
25 Mill shares were sold on Sep 4, but this one intended that $25 million dollars were raised. It seems There is no better financing.
Offered 25 Mill shares not dollars
I still think so too, but I’m reducing to the minimum number of shares that would pay the mortgage at $10 / share after taxes.
No real chance of a reverse split and no real chance of an organic uplist. OTC hell will continue.
No way, not until there is major financing. And not until volume DRAMATICALLY increases. Otherwise a r/s is doomed to failure.
It would take a *remarkable* screwup to avoid a reasonable valuation, but that is still not beyond the realm of possibility; given the Pourhassan ... magnetism.
We know about the 27 Mill for Prostagene, and the presumed long-awaited-get-us-to-the-finish-line decent financing. <breathe> And room for cancer trials.
IHub is too glitchy today
Lowered expectations. The entire 2.5 years that I’ve been long, I’ve had to continually lower my short and intermediate expectations, because they’ve never been met. My theoretical long term expectations are higher than they’ve ever been. Were they too high to begin with ? Yes. More my fault than the company’s fault or FDAs fault. Over this time my confidence has eroded such that
Better than the 700 to 750 Mill I was thinking.
So you are saying Nader is the reason why the stock is at a nadir ?
I heard that the earliest the deal could be finalized was November, and given CYDY’s history concerning timelines, make that January.
If Pestell was now CEO, do you think for a second, that we would have any financing problems ?
Why is he still ceo ? Why not Tony C or maybe Pestell ? The best thing that happened to GALT was getting rid of Dr Traber. The company deserves someone more qualified than Nader.
I’m not holding my breath.
There used to be a time when CYDY did not trade in line with other bios each day. Now it seems to. I suppose that is an improvement.
Doesn’t take much to knock it down, but takes a lot to drive it back up. Fortunately the last leg up was on only 1/3 the volume of the previous leg up.
But it can be done, right ? Whoever acquires HIV can also buy a portion of cancer rights but allow that to remain under CYDY or an entity created at buyout.
“Let’s meet in Vegas when the stock skyrockets !” That’s what is said on the CYDY board also. Price Still lower than it was 3 years ago.
BP would wait at least until phase 2 is done. Phase 2 cancer trials won’t be over until 2020. Mono HIV will be over before that. Market cap could get CRA-Zeee by then.
Some of us said that two years ago. Why would now be any different from then. We have PE in phase 3, a world class cancer researcher, but that hasn’t mattered .... yet. But when ? When the idiots on the street realize that Pro140 is going to be approved. I don’t think that will be until either the FDA actually says it’s approved, or until CYDY has about nine figures in cash. Not a moment sooner.
But this assumes approved cancer therapies, right ? We have only finished a few preclinicals.
Sure, a couple billion here, a couple billion there .... eventually that adds up to a significant amount of money. Thanks.
The money that follows Dr Pestell around, of course.
I asked for a clarification on this, and as always, I received no information.
And then they will apply for an IND ?
But when will those trials begin ? Late next month or late next year ? Do they have an approved phase 2 protocol or have they not yet submitted IND’s ? Who can tell ?
What is there to react to ? How far along in the process is it ? We have no idea; so the market will ignore it, IMO.
Yes, your IMO’s are always welcome Misiu ! Thanks, I had forgotten GvHD has jumped in at Phase 2.
The lack of details suggests it is very, very early. Phase 1 definitely wouldn’t begin until 2019 is what I’m thinking.
At what step in the process are they with the FDA for breast cancer ? Have they submitted an IND ? Have they submitted a phase 1 protocol ? Or do they hope to one day still do those things ? I can’t really tell.